µÚÒ»·¶ÎÄÍø - רҵÎÄÕ·¶ÀýÎĵµ×ÊÁÏ·ÖÏíÆ½Ì¨

Áù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼Á¶Ô·Î - Ê¡ÂÔ - - IL - 4 - IL - 10±í´ïµÄÓ°Ïì - ÁõÃô - ͼÎÄ

À´Ô´£ºÓû§·ÖÏí ʱ¼ä£º2025/5/23 23:56:13 ±¾ÎÄÓÉloading ·ÖÏí ÏÂÔØÕâÆªÎĵµÊÖ»ú°æ
˵Ã÷£ºÎÄÕÂÄÚÈݽö¹©Ô¤ÀÀ£¬²¿·ÖÄÚÈÝ¿ÉÄܲ»È«£¬ÐèÒªÍêÕûÎĵµ»òÕßÐèÒª¸´ÖÆÄÚÈÝ£¬ÇëÏÂÔØwordºóʹÓá£ÏÂÔØwordÓÐÎÊÌâÇëÌí¼Ó΢ÐźÅ:xxxxxxx»òQQ£ºxxxxxx ´¦Àí£¨¾¡¿ÉÄܸøÄúÌṩÍêÕûÎĵµ£©£¬¸ÐлÄúµÄÖ§³ÖÓëÁ½⡣

µÚ39¾íµÚ1ÆÚ

CHINESE

ÖлªÖÐ

OF

ҽҩѧ¿¯

MEDICINE

Vol£®39No£®1Jan£®2021

2021Äê1ÔÂA£ÒCHIVEST£ÒADITIONALCHINESE

DOI£º10£®13193/j£®issn£®1673-7717£®2021£®01£®023

Áù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼Á¶Ô·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­ÁÙ´²Ô¤ºó

IL£­4¡¢IL£­10±í´ïµÄÓ°Ïì¼°IFN£­¦Ã¡¢

ÁõÃô£¬Â¬ÌïÌð

£¨ÖÐÄÏ´óÑ§ÏæÑÅҽѧԺ¸½Êôº£¿ÚÒ½Ôº£¬º£ÄϺ£¿Ú570208£©

IL£­4¡¢IL£­10±í´ïµÄÓ°ÕªÒª£ºÄ¿µÄÁù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼Á¶Ô·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­ÁÙ´²Ô¤ºó¼°IFN£­¦Ã¡¢

Ïì¡£·½·¨Ñ¡Ôñ2016Äê4Ô¡ª2018Äê3ÔÂÔÚÒ½ÔºÕï¶ÏΪ·ÎÆ¢ÆøÐéÐÍÏø´­»¼¶ù¹²120Àý£¬°´ÕÕÈë×é˳ÐòËæ»ú¾ù·ÖΪÁ½×飬·Ö×é·½·¨ÒÀ¾ÝËæ»úÊý×Ö±í·¨¡£Èë×éºó¶ÔÕÕ×鏸Óè°×ÈýÏ©ÊÜÌåÞ׿¹¼Áµ¥Ò©ÖÎÁÆ£»Í¬Ê±ÖÎÁÆ×éʹÓÃÁù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÖÎÁÆ¡£¹Û²ìÁ½×黼ÕßÁÙ´²ÁÆÐ§£¬²¢¶ÔÁ½×黼ÕßÖÎÁÆÇ°ºóÖÐÒ½Ö¢ºò»ý·Ö¡¢·Î¹¦ÄܽøÐбȽϣ¬¼ì²â»¼ÕßѪÇ壬±È½ÏÁ½

IL£­4¡¢IL£­10¡£½á¹ûÖÎÁÆ×é×ÜÓÐЧÂÊÃ÷ÏÔ¸ßÓÚ¶ÔÕÕ×飬ÁÙ´²ÖÎÁÆÐ§¹ûÃ÷ÏÔÓÅÓÚ¶ÔÕÕ×飨P£¼0.05£©£»×éÖÎÁÆÇ°ºóIFN£­¦Ã¡¢

ÖÎÁÆ×éÖÐÒ½Ö¢ºò»ý·Ö½Ï¶ÔÕÕ×éÏÔÖø½µµÍ£¨P£¼0.05£©£»ÖÎÁÆ×é·Î¹¦ÄÜÖ¸±êFEV1¼°PEF¾ù½Ï¶ÔÕÕ×é¸ÄÉÆÏÔÖø£¨P£¼0.05£©£»

IL£­10ÏÔÖøÉý¸ß£¬IL£­4ÔòÏÔÖø½µµÍ£¨P£¼0.05£©¡£½áÂÛÁù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÓÐЧÖÎÁÆ×é½Ï¶ÔÕÕ×éIFN£­¦Ã¡¢

IL£­4¡¢IL£­10µÄ±í´ï¡£ÓÐЧ¸ÄÉÆIFN£­¦Ã¡¢Ìá¸ß·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­ÁÙ´²ÖÎÁÆÐ§¹û¼°ÆäÔ¤ºó£¬

¹Ø¼ü´Ê£ºÁù¾ý×ÓÌÀ£»°×ÈýÏ©ÊÜÌåÞ׿¹¼Á£»·ÎÆ¢ÆøÐé£»Ïø´­£»IFN£­¦Ã£»IL£­4£»IL£­10

7717£¨2021£©01-0086-03ÖÐͼ·ÖÀàºÅ£º£Ò256£®12ÎÄÏ×±êÖ¾Â룺AÎÄÕ±àºÅ£º1673-

EffectofLiujunziDecoction£¨Áù¾ý×ÓÌÀ£©CombinedwithLeukotriene£ÒeceptorAntagoniston

ClinicalPrognosisandExpressionsofIFN£­¦Ã£¬IL£­4andIL£­10inChildren

withLung£­SpleenQiDeficiency

LIUMin£¬LUTiantian

£¨AffiliatedHaikouHospitalofXiangyaMedicalCollege£¬CentralSouthUniversity£¬Haikou570208£¬Hainan£¬China£©

Abstract£ºObjectiveLiujunziDecoction£¨Áù¾ý×ÓÌÀ£©combinedwithleukotrienereceptorantagonistsontheclinicalprognosisandexpressionsofIFN£­¦Ã£¬IL£­4andIL£­10inchildrenwithlung£­spleenQideficiency£®MethodsAtotalof120childrenwithadiagnosisofasthmawithlung£­spleenQideficiencysyndromefromApril2016toMarch2018wereenrolledinthisstudy£®Theywererandomlydividedintotwogroupsaccordingtotheenrollmentorder£®Thegroupingmethodwasbasedontherandomnumbertablemethod£®Aftertheenrollment£¬thecontrolgroupwasgivenmonotherapywithleukotrienereceptorantagonist£®ThetreatmentgroupwastreatedwithLiujunziDecoctioncombinedwithleukotrienereceptorantagonist£®Theclinicalefficacyofthetwogroupswasobserved£®TheTCMsyndromescoresandlungfunctionwerecomparedbeforeandaftertreatment£®Theserumofthepatientswasdetected£®ThelevelsofIFN£­¦Ã£¬IL£­4andIL£­10werecomparedbeforeandaftertreatment£®£ÒesultsThetotaleffectiverateofthetreatmentgroupwassignificantlyhigherthanthatofthecontrolgroup£®Theclinicaltreatmenteffectwassignificantlybetterthanthatofthecontrolgroup£¨P£¼0.05£©£®TheTCMsyndromescoreofthetreatmentgroupwassignificantlylowerthanthatofthecontrolgroup£¨P£¼0.05£©£®ThelungfunctionindexesofthetreatmentgroupwereFEV1andPEF£®Comparedwiththatofthecontrolgroup£¬theimprovementwassignificant£¨P£¼0.05£©£®Comparedwiththoseofthecontrolgroup£¬thelevelsofIFN£­¦ÃandIL£­10weresignificantlyincreased£¬whilethelevelofIL£­4wassignificantlydecreased£¨P£¼0.05£©£®ConclusionLiujunziDecoctioncombinedwithleukotrienereceptorantagonistcaneffectivelyimprovetheclinicaltherapeuticeffectandprognosisofasthmachildrenwithlung£­spleenQideficiencysyndromeandeffectivelyimprovetheexpressionsofIFN£­¦Ã£¬IL£­4andIL£­10£®

Keywords£ºLiujunziDecoction£¨Áù¾ý×ÓÌÀ£©£»leukotrienereceptorantagonist£»lung£­spleenQideficiency£»asthma£»IFN£­¦Ã£»IL£­4£»IL£­10

¡£¾Ýͳ¼Æ£¬Ïø´­ÊǶùͯÖÐ×î³£¼ûµÄÂýÐÔ¼²²¡Ö®Ò»½üÄê

À´È«ÇòÏø´­»¼Õß³ÊÖðÄêÉÏÉýµÄÇ÷ÊÆ£¬¶ø¶ùÍ¯Ïø´­µÄ·¢²¡ÂʸüÊÇ

»ù½ðÏîÄ¿£º¹ú¼ÒÖÐÒ½Ò©¹ÜÀí¾ÖÖÐÒ½Ò©ÐÐÒµ¿ÆÑÐÏîÄ¿£¨20170833£©×÷Õß¼ò½é£ºÁõÃô£¨1983£­£©£¬Å®£¬ºþÄϦµ×ÈË£¬Ö÷ÖÎҽʦ£¬Ñ§Ê¿£¬Ñо¿·½Ïò£º

¶ù¿Æ¡£

£Û1£­2£Ý

Ôö¼ÓÁËÒ»°ëÒÔÉÏ¡£Óë´Ëͬʱ£¬¶ùÍ¯Ïø´­µÄ¿ØÖÆÂÊÈ´²»ÈÝÀÖ

¹Û£¬Ò»°ëÒÔÉϵĶùÍ¯Ïø´­»¼Õß¾ù³öÏÖ¼±ÐÔ·¢×÷£¬ÖÁÉÙËÄ·ÖÖ®Ò»

£Û4£Ý

µÄ¶ùͯҲÒò´ËÐèÒª¼±¾ÈÖÎÁÆ¡£Ïø´­ÏÔÖøÓ°Ïì×ŶùͯµÄ½¡¿µ

£Û5£Ý

·¢Óý£¬Í¬Ê±ÎªÆä¼ÒÍ¥´øÀ´³ÁÖØµÄ¸ºµ£¡£ÔÚÁÙ´²ÖÐËù¼ûÏø´­»¼¶ù¶àΪÑǽ¡¿µ×´Ì¬£¬Òò´ËÓÕ·¢Ïø´­µÄÒòËØ¶ÔÆäÀ´Ëµ¸üΪÃô¸Ð£¬¶ÔÓÚÕâÖÖ»¼¶ùÀ´Ëµ£¬µ¥´¿µÄʹÓó£ÓõÄÎüÈë¼¤ËØÎÞ·¨ÓÐЧ

£Û3£Ý

86

µÚ39¾íµÚ1ÆÚ

CHINESE

ÖлªÖÐ

OF

ҽҩѧ¿¯

MEDICINE

Vol£®39No£®1Jan£®2021

2021Äê1ÔÂA£ÒCHIVEST£ÒADITIONALCHINESE

£Û6£­7£Ý

¡£¿öÇÒ³¤ÆÚʹÓü¤ËضÔÓÚ»¼¶ù½â¾ö¶ùÍ¯Ïø´­µÄÕæÕýÎÊÌâ·¢ÏÖÉÙÐíÆøµÀ·ÖÃÚÎÎÞЧ£ºÁÙ´²±íÏÖ¼°Ó°Ïñѧ¹Û²ìÃ÷ÏÔºÃת£¬

Ïñѧδ·¢Ïֱ仯£¬ÈÔ·¢ÏÖ½Ï¶àÆøµÀ·ÖÃÚÎï¡£×ÜÓÐЧÂÊ=£¨ÏÔЧÀ´Ëµ£¬Ò²²»ÀûÓÚÆäÕý³£µÄÉú³¤·¢Óý¡£½üЩÄêÀ´£¬¶àÏîÑо¿¶¼Ö¤

ÀýÊý+ÓÐЧÀýÊý£©/×ÜÀýÊý¡Á100%¡£ÊµÁËÖÐÒ½Ò©ÔÚÏø´­·½ÃæµÄ¶ÀÌØ×÷Óá£ÖÐҽѧÈÏÎªÏø´­ÊôÓÚ

¡°´­Ö¤¡±¡°Ïø²¡¡±·Î¹¦ÄÜ£ºÔÚ»¼¶ùÖÎÁÆÇ°12ÖÜÓëÖÎÁƺó12ÖܲⶨµÚ1Ãë×îµÈ·¶³ë£¬ÆäÃèÊöµÄ¼²²¡»úÀíÓëÏÖ´úËùνµäÐÍÏø

¡°ÄÚÒò¡±¡°ÍâÒò¡±£¬´óºôÆøÁ¿£¨FEV1£©ºÍ×î´óºôÆøÁ÷Á¿£¨PEF£©¡£´­ÏàËÆ£¬²¡ÒòÖ÷Òª·ÖΪÄÚÒò°üº¬ÒÅ´«¡¢ÌåÖÆ¡¢·ü

ÖÐÒ½Ö¢×´»ý·Ö£ºÖÎÁÆÇ°12ÖÜÓëÖÎÁƺó12ÖܶԻ¼¶ùÏøÃùÍâ¸ÐÖ÷ÒªÒÔÁùÒùΪÖ÷£¬¼æ¼ûÒûʳ²»½Ú£¬À;ëËùÉË£¬ÄÚ̵µÈÒòËØ£¬

¿ÈËÔ¡¢´­Ï¢¡¢¿È̵»ý·Ö¼ÆË㣬¸ù¾ÝÖ¢×´µÄ·Ö¼¶ÎªÃ¿Ò»¸öÖ¸±êÒô¡¢ÉËÇéÖ¾µÈ¡£Í¨¹ýÖÐÒ½µÄÖÎÁÆ£¬¿ÉÒÔÓÐЧ»º½âÏø´­ÁÙ´²Ö¢×´£¬°ï

£Û8£Ý

»ý·Ö£¬ÎÞ0·Ö£¬Çá1·Ö£¬ÖÐ2·Ö£¬ÖØ4·Ö¡£Ìá¸ßÉú»îÖÊÁ¿¡£±¾Ñо¿¹Û²ìÁù¾ý×ÓÌÀÁªÖú»¼Õ߻ָ´½¡¿µ£¬

ʵÑéÊÒÖ¸±ê£º²É¼¯»¼¶ùÖÎÁÆÇ°¼°ÖÎÁƺó5¡«8hÄÚµÄÖⲿºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼Á¶Ô·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­ÁÙ´²Ô¤ºó¼°IFN£­

¾²ÂöѪ£¬²ÉÓÃDG5033Aø±êÒÇ£¨ÄϾ©»ª¶«µç×ӿƼ¼¹«Ë¾£©½øÐÐIL£­4¡¢IL£­10±í´ïµÄÓ°Ï죬¦Ã¡¢ÏÖ±¨µÀÈçÏ¡£

ODÖµ¼ì²â£¬IL£­4¡¢IL£­10¡£¼ì²â»¼ÕßIFN£­¦Ã¡¢1×ÊÁÏÓë·½·¨

1£®4ͳ¼ÆÑ§·ÖÎöÑ¡ÔñSPSS21£®0½øÐÐÊý¾Ýͳ¼Æ£¬Êý¾Ý²ÉÓÃ1£®1Ò»°ã×ÊÁÏѡȡÎÒÔº2017Äê2Ô¡ª2018Äê3ÔÂµÄ·ÎÆ¢

«€x¡ÀsÀ´±íʾ£¬¼ÆÁ¿×ÊÁϵıȽϲÉÓÃt¼ìÑ飬¼ÆÊý×ÊÁÏµÄ±È½Ï²ÉÆäÖÐÄÐ60Àý£¬Æ½¾ùÄêÁ䣨9£®5¡À1£®6£©ÆøÐéÐÍÏø´­»¼¶ù120Àý£¬

2

ÓæּìÑ飬P£¼0.05ʱ£¬²îÒì¾ßÓÐͳ¼ÆÑ§ÒâÒå¡£ËꣻŮ60Àý£¬Æ½¾ùÄêÁ䣨8£®5¡À1£®3£©Ëê¡£°´ÕÕÈë×é˳ÐòËæ»ú·ÖΪ

2½á¹ûÿ×é60Àý£¬·Ö×é·½·¨¸ù¾ÝËæ»úÊý×Ö±í·¨£¬Á½×é»ù±¾×ÊÁÏÁ½×飬

2£®1Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­»¼ÕßÁÙ´²ÁÆÐ§¶Ô±ÈÖÎÁÆ×é×ܲîÒìÎÞͳ¼ÆÑ§ÒâÒ壨P£¾0.05£©£¬¾ßÓпɱÈÐÔ¡£

ÓÐЧÂÊΪ95£®00%£»¶ÔÕÕ×é×ÜÓÐЧÂÊΪ73£®33%¡£Á½×éÏà±È£¬ÄÉÈë±ê×¼£º·ûºÏÏø´­»ù±¾Õï¶Ï±ê×¼£»ÖÐÒ½±æÖ¤ÊôÓÚ·ÎÆ¢Æø

ÖÎÁÆ×é×ÜÓÐЧÂÊÊýÃ÷ÏÔ¸ßÓÚ¶ÔÕÕ×飬ÁÙ´²ÖÎÁÆÐ§¹ûÏÔÖøÓÅÓÚÐéÐÍÏø´­£»ÄêÁä7¡«12Ëꣻ»¼¶ù·¨¶¨¼à»¤ÈËÖªÇ鲢ͬÒâ¡£

¶ÔÕÕ×飨P£¼0.05£©¡£¼û±í1¡£Åųý±ê×¼£ººÏ²¢¸Î¡¢ÉöµÈÑÏÖØ¼²²¡£»¶ñÐÔÖ×Áö»¼Õߣ»·¨¶¨¼à

±í1Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­»¼ÕßÁÙ´²ÁÆÐ§±È½Ï»¤È˲»Í¬ÒâͬÒâ»ò»¼¶ùÎÞ·¨ÅäºÏÍê³ÉÑо¿Õߵȡ£

µ¥Î»£ºÀý£¨%£©1£®2·½·¨¶ÔÕÕ×黼¶ù¸øÓèÃÏÂ³Ë¾ÌØÄÆÆ¬£¨Ë³¶ûÄþ£¬Éú²ú³§

1´Î¡¤d£­1£¬¼Ò£ºÄ¬É³¶«£¬½ø¿ÚÒ©Æ·×¢²áÖ¤ºÅ£ºH20120360£©£¬Ã¿×é±ðÀýÊýÏÔЧÓÐЧÎÞЧ×ÜÓÐЧ

´Î1Ƭ£¨4mg£©£»ÖÎÁÆ×黼¶ùÔÚÃÏÂ³Ë¾ÌØÄÆÆ¬µÄ»ù´¡ÖÎÁÆÉÏÁª6039£¨65£®00£©18£¨30£®00£©3£¨5£®00£©ÖÎÁÆ×é57£¨95£®00£©*

6026£¨43£®33£©18£¨30£®00£©16£¨26£®67£©44£¨73£®33£©¶ÔÕÕ×éÜòÜß9g£¬°×Êõ9g£¬°ëÏÄ9g£¬ºÏÁù¾ý×ÓÌÀ£¨Ò©Îï×é³É£ºÈ˲Î9g£¬

£­1

1¼Á¡¤d£¬P£¼0.05¡£³ÂƤ9g£¬¸Ê²Ý6g£©£¬Ë®¼å·þ£¬ÔçÍí¸÷1´Î¡£Á½×黼ע£º*Óë¶ÔÕÕ×é±È½Ï£¬

2£®2Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­»¼ÕßÖÎÁÆÇ°ºóÖÐÒ½Ö¢ºò»ý·Ö±È¶ù¸øÓèÖÎÁƹ²3¸öÔ¡£

1£®3¹Û²ìÖ¸±êÁÆÐ§Åжϱê×¼£ºÏÔЧ£ºÁÙ´²±íÏÖ¼°Ó°Ïñѧ֤Ã÷¿ÈËÔ¡¢´­Ï¢¡¢¿È̵µÄÖÐÒ½Ö¢ºò»ý·Ö¾ù½Ï¶ÔÕÕ½ÏÖÎÁÆ×éÏøÃùÒô¡¢

×é¸ÄÉÆÏÔÖø£¨P£¼0.05£©¡£¼û±í2¡£Î´·¢ÏÖÆøµÀ·ÖÃÚÎÓÐЧ£ºÁÙ´²±íÏÖ¼°Ó°½ÏǰÎüÊÕ95%ÒÔÉÏ£¬

«€¡Às£©±í2Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­»¼ÕßÖÎÁÆÇ°ºóÖÐÒ½Ö¢ºò»ý·Ö±È½Ï£¨xµ¥Î»£º·Ö

×é±ðÖÎÁÆ×é¶ÔÕÕ×é

ÀýÊý6060

ÏøÃùÒô

ÖÎÁÆÇ°2£®67¡À0£®212£®70¡À0£®37

ÖÎÁƺó0£®69¡À0£®27*1£®54¡À0£®44*

#

¿ÈËÔ

ÖÎÁÆÇ°2£®81¡À0£®352£®96¡À0£®34

ÖÎÁƺó0£®72¡À0£®06*1£®35¡À0£®28*

#

´­Ï¢

ÖÎÁÆÇ°2£®88¡À0£®332£®86¡À0£®35

ÖÎÁƺó0£®65¡À0£®08*1£®36¡À0£®19*

#

¿È̵

ÖÎÁÆÇ°2£®98¡À0£®232£®76¡À0£®85

ÖÎÁƺó0£®50¡À0£®76*1£®65¡À0£®75*

#

P£¼0.05£»#Óë¶ÔÕÕ×é±È½Ï£¬P£¼0.05¡£×¢£º*ÓëÖÎÁÆÇ°±È½Ï£¬

2£®3

Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­»¼ÕßÖÎÁÆÇ°ºó·Î¹¦ÄܱȽÏÖÎ

ÁÆ×éFEV1¼°PEF½Ï¶ÔÕÕ×é¸ÄÉÆÏÔÖø£¨P£¼0.05£©¡£¼û±í3¡£

±í3Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­»¼ÕßÖÎÁÆ

«€¡Às£©Ç°ºó·Î¹¦ÄܱȽϣ¨x

×é±ðÖÎÁÆ×é¶ÔÕÕ×éÀýÊý6060FEV1/£¨L£©ÖÎÁÆÇ°1£®29¡À0£®181£®28¡À0£®17ÖÎÁƺó1£®54¡À0£®23*#

0.05£©¡£¼û±í4¡£3ÌÖÂÛ

Ëæ×ÅÏÖ½ñÉç»áÏø´­¼²²¡·¢²¡Âʲ»¶ÏÉÏÉý£¬µ¼Ö¶ùͯ»¼Õß²¡ËÀÂʼ°Ö²ÐÂʲ»¶ÏÉÏÉý£¬ÏÔÖøÔö¼ÓÁË»¼¶ùµÄÉú»îÖÊÁ¿¼°Æä¼ÒÈË

£Û9£­11£Ý

¡£ÈËÃǶÔÏø´­µÄ·¢²¡»úÖÆÒ²²»¶ÏËæ×ÅÏø´­·¢²¡»ú¶î¸ºµ£

ÖÆµÄ²»¶ÏÑо¿Ì½Ë÷¡£³ýÒÅ´«¡¢ÃâÒß¡¢»·¾³µÈÒòËØÍ⣬ÏÖ´úÁÙ´²»¹

Tϸ°û¼°·Ê´óϸ°ûµÈ¶àÖÖÆÕ±éÈÏΪ£¬Ïø´­ÊÇÓÉÊÈËáÐÔÁ£Ï¸°û¡¢

£Û12£­14£Ý

¡£ÔÚ²¡Àí·¢Õ¹ÀàµÄÑ×ÐÔϸ°û¹²Í¬²ÎÓëµÄÆø¹ÜÂýÐÔÑ×Ö¢

ÖУ¬²»Í¬µÄÑ×֢ϸ°ûÏ໥×÷Óã¬ÆøµÀµÄ±íƤϸ°ûÊܵ½ÁËËðÉË£¬ÒýÆð΢Ѫ¹ÜµÄÀ©ÕÅºÍÆäͨ͸ÐÔÉý¸ß£¬×îÖÕÑ×ÐÔϸ°û´ÙÊ¹Ö§Æø¹ÜµÄ

£Û15£­18£Ý

¡£Ñо¿ÏÔʾ£¬µ¼Ö¸ò¡²»¶Ï·¢×÷ÏøÊÕËõºÍÆä½á¹¹µÄ±ä»¯£¬

µ¥Î»£ºng¡¤L

IL£­10

ÖÎÁƺó8£®77¡À3£®16*25£®88¡À6£®88*

#

£­1

PEF/£¨L¡¤s£­1£©ÖÎÁÆÇ°3£®33¡À0£®453£®38¡À0£®41ÖÎÁƺó4£®91¡À0£®48*4£®11¡À0£®49*

#

1£®44¡À0£®11*

P£¼0.05£»#Óë¶ÔÕÕ×é±È½Ï£¬P£¼0.05¡£×¢£º*ÓëÖÎÁÆÇ°±È½Ï£¬2£®4

Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­»¼ÕßÖÎÁÆÇ°ºóʵÑéÊÒÖ¸±ê±È½ÏIL£­4¡¢IL£­10¾ù½Ï¶ÔÕÕ×é¸ÄÉÆÏÔÖø£¨P£¼ÖÎÁÆ×éIFN£­¦Ã¡¢

«€¡Às£©±í4Á½×é·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­»¼ÕßÖÎÁÆÇ°ºóʵÑéÊÒÖ¸±ê±È½Ï£¨x

×é±ðÖÎÁÆ×é¶ÔÕÕ×é

ÀýÊý6060

IFN£­¦Ã

ÖÎÁÆÇ°135£®65¡À14£®59136£®74¡À13£®46

ÖÎÁƺó213£®25¡À18£®79*146£®33¡À16£®98*

#

IL£­4

ÖÎÁÆÇ°29£®19¡À8£®7728£®33¡À9£®22

ÖÎÁÆÇ°18£®46¡À4£®9516£®60¡À4£®64

ÖÎÁƺó33£®25¡À4£®68*22£®44¡À6£®65*

#

P£¼0.05£»#Óë¶ÔÕÕ×é±È½Ï£¬P£¼0.05¡£×¢£º*ÓëÖÎÁÆÇ°±È½Ï£¬

87

µÚ39¾íµÚ1ÆÚ

CHINESE

ÖлªÖÐ

OF

ҽҩѧ¿¯

MEDICINE

Vol£®39No£®1Jan£®2021

2021Äê1ÔÂA£ÒCHIVEST£ÒADITIONALCHINESE

IL£­4¡¢IL£­10ÔÚÏø´­²¡Àí»úÖÆÖз¢»Ó´­»¼ÕßѪÇåÄÚIFN£­¦Ã¡¢

ÖØÒª×÷Óã¬Äܹ»½ÒÊ¾Ïø´­²¡Àí½øÕ¹»úÖÆ£¬ÊÇÆÀ¼Û¶ùÍ¯Ïø´­ÖØÒªµÄÆÀ¼ÛÖ¸±ê

£Û19£Ý

£®ÁÙ´²Ò½Ñ§Ñо¿Óëʵ¼ù£¬2018£¬3£¨18£©£ºÆø¹ÜÏø´­µÄÁÙ´²Ð§¹û£ÛJ£Ý123£­124£®

£Û9£ÝÂíЧ¶«£®Áù¾ý×ÓÌÀ¼Ó¼õÖÎÁÆÐ¡¶ùÖ§Æø¹ÜÏø´­µÄÁÆÐ§¼°¶ÔÃâÒß¹¦

J£Ý£®È«¿ÆÒ½Ñ§ÁÙ´²Óë½ÌÓý£¬2018£¬16£¨1£©£º82£­84£®ÄܵÄÓ°Ïì£Û

£Û10£ÝÕÅÁ¢±ò£®ÖÐÎ÷Ò½½áºÏÖÎÁÆÏø´­Õï¶Ï·ÖÎö£ÛJ£Ý£®Òûʳ±£½¡£¬2016£¬3

£¨2£©£º196£­197£®

£Û11£ÝÄôÁ¦£¬¸ðÎÀºì£®°×ÈýÏ©ÊÜÌåÞ׿¹¼Á¸ÄÉÆÏø´­»¼ÕßÑ×Ö¢¼°ÃâÒß¹¦

2017£¬35£¨6£©£º562£­564£¬568£®ÄܵÄЧ¹û·ÖÎö£ÛJ£Ý£®Ò©Ñ§Êµ¼ùÔÓÖ¾£¬

£Û12£ÝÖìϼ£¬¼ÖÎÀ»ª£®è×½ÛÁù¾ý×ÓÌÀ¼Ó¼õÁªºÏɳÃÀÌØÂÞÌæ¿¨ËÉ·ÛÎüÈë

£®ÖйúÃñ¼äÁÆ·¨£¬2018£¬26¼ÁÖÎÁÆÖ§Æø¹ÜÏø´­µÄÁÙ´²¹Û²ì£ÛJ£Ý£¨9£©£º63£­64£®

£Û13£ÝÁºÑÞ¾ù£¬ÖÜÁ¢Ô¶£¬Íõ¼ÒÕ䣮°×ÈýÏ©Þ׿¹¼ÁÁªºÏÊæÀûµüÔÚÏø´­ÖÎÁÆ

2016£¬10£¨16£©£º1£­ÖеÄÓ¦ÓÃÒâÒå̽¾¿£ÛJ£Ý£®ÖйúÏÖ´úÒ©ÎïÓ¦Óã¬3£®

£Û14£ÝÍò³Ï£¬Ð¤²¨£®·Î¡¢Æ¢¡¢ÉöÈýÔàͬÖλº½âÆÚÖ§Æø¹ÜÏø´­50ÀýÁÙ´²¹Û

J£Ý£®¹ã¶«Ò½Ñ§ÔºÑ§±¨£¬2016£¬34£¨2£©£º194£­196£®²ì£Û

£Û15£ÝBUTLE£ÒCT£¬£ÒEYNOLDSAL£¬TOSETTOM£¬etal£®AQuininib

AnalogueandCysteinylLeukotriene£ÒeceptorAntagonistInhibitsVascularEndothelialGrowthFactor£¨VEGF£©£­independentAngio-genesisandExertsanAdditiveAntiangiogenic£ÒesponsewithBev-acizumab£ÛJ£Ý£®JBiolChem£¬2017£¬292£¨9£©£º3552£­3567£®

£Û16£ÝÕÅ»ÝæÃ£¬ÕÅÀöÄÈ£®°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÁªºÏÌÇÆ¤Öʼ¤ËØÖÎÁÆÐ¡¶ù¿È

J£Ý£®¼ªÁÖҽҩѧԺѧ±¨£¬2019£¬40£¨3£©£º222£­224£®ËÔ±äÒìÐÔÏø´­£Û

£Û17£Ý·ëÃô¾ê£®°×ÈýÏ©ÊÜÌåÞ׿¹¼Á°×Èýƽ¶ÔС¶ùÏø´­µÄÓÐЧÐÔ̽ÌÖ

£ÛJ£Ý£®´ó¼Ò½¡¿µ£¨ÉÏÑ®°æ£©£¬2017£¬11£¨10£©£º206£®

£Û18£ÝOKUBOK£¬HASHIGUCHIK£¬TAKEDAT£¬etal£®Arandomized

controlledphaseIIclinicaltrialcomparingONO£­4053£¬anovelDP1antagonist£¬withaleukotrienereceptorantagonistpranlukastinpatientswithseasonalallergicrhinitis£ÛJ£Ý£®Allergy£¬2017£¬72£¨10£©£º1565£­1575£®

£Û19£Ý·®ÕêÓñ£¬ÖÜѩ÷£¬ÏãÀûºì£¬µÈ£®°×ÈýÏ©Þ׿¹¼ÁÁªºÏÎüÈëÊæÀûµüÖÎ

2017£¬33ÁÆÀÏÄêÏø´­»¼ÕßµÄÁÙ´²Ð§¹û·ÖÎö£ÛJ£Ý£®ÖйúÉçÇøÒ½Ê¦£¬£¨31£©£º32£­33£®

£Û20£ÝÉê¹ãÉú£¬Íõ¾ê£®Áù¾ý×ÓÌÀºÏÓñÆÁ·çÉ¢ÖÎÁƶùÍ¯Ïø´­²¢·´¸´ºôÎü

2018£¬33£¨21£©£º3124£­3126£®µÀ¸ÐȾµÄ¼ÛÖµ£ÛJ£Ý£®¹âÃ÷ÖÐÒ½£¬

£Û21£Ý²ÜÇåÔÆ£®°×ÈýÏ©Þ׿¹¼ÁÁªºÏÎüÈëÊæÀûµüÖÎÁÆÀÏÄêÏø´­µÄÁÙ´²ÑÐ

J£Ý£®ÖÐÎ÷Ò½½áºÏÐÄѪ¹Ü²¡µç×ÓÔÓÖ¾£¬2017£¬5£¨1£©£º87£®¾¿£Û

£Û22£ÝÀîÎÄóÞ£®°×ÈýÏ©Þ׿¹¼ÁÁªºÏÎüÈëÌÇÆ¤Öʼ¤ËضÔÀÏÄêÏø´­»¼Õß·Î

£®ÁÙ´²Ò½Ò©ÎÄÏ×µç×ÓÔÓÖ¾£¬2017£¬4¹¦Äܼ°Éú´æÖÊÁ¿µÄÓ°Ïì£ÛJ£Ý£¨40£©£º7876£­7877£®

£Û23£ÝFITZPAT£ÒICKAM£¬JACKSONDJ£¬MAUGE£ÒDT£¬etal£®Individ-ualizedtherapyforpersistentasthmainyoungchildren£ÛJ£Ý£®JAllergyClinImmunol£¬2016£¬138£¨6£©£º1608£­1618£®

£Û24£Ý¹ùÀ裬±ß¿¡Ã·£®ÁªºÏʹÓð×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÖÎÁƶùͯ¿ÈËÔ±äÒìÐÍ

J£Ý£®ÊµÓÃÁÙ´²Ò½Ò©ÔÓÖ¾£¬2017£¬21£¨3£©£º203£­205£®Ïø´­µÄÁÙ´²Ñо¿£Û

£Û25£Ý²ÌƼ£®Áù¾ý×ÓÌÀºÏÓñÆÁ·çÉ¢ÖÎÁÆÓ¤Ó×¶ùÏø´­²¢·´¸´ºôÎüµÀ¸ÐȾ

J£Ý£®´ó¼Ò½¡¿µ£¨ÖÐÑ®°æ£©£¬2017£¬11£¨6£©£º192£®µÄ¼ÛÖµ£Û

£Û26£ÝCHAUHANBF£¬JEYA£ÒAMANMM£¬SINGHMANNA£¬etal£®Addi-tionofanti£­leukotrieneagentstoinhaledcorticosteroidsforadults£®CochraneDatabaseSystandadolescentswithpersistentasthma£ÛJ£Ý£Òev£¬2017£¬3£ºCD010347£®

£Û27£ÝФÀö£®Áù¾ý×ÓÌÀºÏÓñÆÁ·çÉ¢ÖÎÁƶùÍ¯Ïø´­²¢·´¸´ºôÎüµÀ¸ÐȾµÄ

J£Ý£®Öйú´¦·½Ò©£¬2017£¬15£¨7£©£º119£­120£®¼ÛÖµ£Û

£Û28£ÝĪΤٻ£¬¼ª´óÕ£¬Âí³¯Ï¼£®°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÁªºÏÎüÈëÐÍÌÇÆ¤ÖÊ

£®ÖйúÏÖ´úÒ©ÎïÓ¦¼¤ËØÖÎÁƶùͯ¿ÈËÔ±äÒìÐÔÏø´­ÁÙ´²¹Û²ì£ÛJ£Ý2019£¬13£¨7£©£º106£­107£®Óã¬

¡£

ÔÚÏø´­²¡Àí¹ý³ÌÖУ¬°×ÈýÏ©ÊÇÒ»ÖÖÖØÒªµÄÑ×ÐÔ·´Ó¦½éÖÊ¡£°×ÈýÏ©¿ÉÒÔÔö¼ÓÆøµÀ×é֯Ѫ¹Üͨ͸ÐÔ£¬´Ù½øð¤Ä¤·ÖÃÚÎïµÄ·ÖʹÊÈËáÐÔÁ£Ï¸°ûÐγɻý¾Û£¬´Ó¶øÒý·¢Æø¹ÜÊÕËõ¡£Õë¶ÔÕâÒ»ÃÚ£¬

²¡ÀíÏÖÏó£¬ÁÙ´²ÖжàÓÃÐÂÒ»´ú·ÇçÞÌ忹Ñ×Ò©°×ÈýÏ©ÊÜÌåÞ׿¹¼Á£¬Æä¿ÉÒÔÓÐЧÒÖÖÆ°×ÈýÏ©µÄ»îÐÔ£¬Ôö¼ÓѪ¹Üͨ͸ÐÔ£¬¼õÉÙÆøµÀÑ×Ö¢½éÖʵIJúÉú£¬×îÖÕ¸ÄÉÆ¶ùÍ¯Ïø´­»¼Õߵķι¦ÄÜ¡£µ«µ¥´¿Ê¹Óð×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÓÃÓÚ¶ùÍ¯Ïø´­ÖÎÁƵĸöÌåÐÔ²îÒì½Ï´ó£¬ÁÙ´²ÖдæÔÚÒ»²¿·Ö¶ùͯ»¼ÕßÖÎÁÆÐ§¹û²»¼Ñ£¬Ò²´Ó¶øÓ°ÏìÁËÆäÖÎÁÆÒÀ´ÓÐÔ

£Û20£­22£Ý

¡£

£¬¡°·ü̵¡±´­Ö¤ÔÚÖÐҽѧÖÐÊÇÒ»ÀàÖØÒªµÄ¼²²¡±»ÈÏΪÊÇ´­

£Û23£­24£Ý

¡£Ö¤·¢²¡×îÖ÷Òª¡¢×îºËÐĵÄÔ­Òò£¬¹ÊÂÛÖζà´Ó¡°Ìµ¡±ÈëÊÖ¡°Ìµ¡±¶ø×÷ΪһÖÖ²¡Àí²úÎÆä²úÉúÖ÷ÒªÓëÈËÌå·Î¡¢Æ¢¡¢ÉöÈý²Ø

Ïà¹Ø£¬ÆäÖÐÓÈÆäÓë·Î¡¢Æ¢Á½²Ø×îΪÃÜÇС£Æ¢ÎªÉú̵֮Դ£¬·ÎΪ´¢ÌµÖ®Æø¡£Æ¢Ð鯸Èô£¬Ë®Òº²»µÃÔË»¯£¬´æÓÚÌåÄÚ¾ÃÔò»¯Ìµ£»·ÎÖ÷ÆøË¾ºôÆø£¬ÈôÆäÆøÐéÔòÆøÐв»³©£¬Ëཱུʧ˾£¬ÎÞ·¨Ê¹Ë®ÊªÕý³£ÔËÐÐ

£Û25£­27£Ý

¡£Í¬Ê±Ð¡¶ù¶àÓÐÏÈÌìÙ÷¸³²»×ã»òºóÌìÊ§Ñø£¬µ¼ÖÂ·ÎÆ¢

£Û28£ÝÐéÈõ£¬ËùÒÔС¶ùÏø´­£¬¶àÒÔ·ÎÆ¢ÆøÐéÐÍΪÖ÷¡£Õë¶ÔÕâÒ»ÁÙ´²Ìص㣬±¾Ñо¿ÔÚ°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁµÄ»ù´¡ÉϼÓÓÃÁËÖÐÒ½¾­µä·½

¼ÁÁù¾ý×ÓÌÀ£¬°üº¬È˲Ρ¢°×Êõ¡¢ÜòÜß¡¢¸Ê²Ý¡¢°ëÏÄ¡¢³ÂƤ¹²6ζ¡£È˲δó²¹ÔªÆø£¬µ÷ÕûÆøÐ飻°×ÊõºÍÖÐ񾮿£¬Ôïʪ»¯Ìµ£»ÜòÜß½¡Æ¢µ÷ºÍÀûË®ÉøÊª£»°ëÏÄÔïʪ»¯Ìµ£»³ÂƤ½¡Æ¢ÀíÆø£»¸Ê²ÝÇåÈȽⶾ£¬ÖîÒ©£»Áùζҩ¹²×àµ÷ÑøÕýÆø£¬ÐÐÆø»¯ÌµÖ®¹¦Ð§¡£±¾Ñо¿²ÉÓÃÁù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÓëµ¥´¿Ê¹Óð×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÏà¶Ô±È£¬Ñо¿½á¹ûÏÔʾ£¬ÖÎÁÆ×éÖÎÁÆ×ÜÓÐЧÂÊÏÔÖø¸ßÓÚ¶ÔÕÕ×飬ÖÎÁƺóÖÎÁÆ×éÏøÃùÒô¡¢¿ÈËÔ¡¢´­Ï¢¡¢¿È̵µÈ

½Ï¶ÔÕÕ×é¶øÑÔ£¬¾ùÖÐÒ½Ö¢ºò»ý·Ö¼°·Î¹¦ÄÜÖ¸±êFEV1¼°PEF£¬

IL£­4¡¢IL£­10¾ù½ÏµÃµ½ÁËÏÔÖøµÄ¸ÄÉÆ¡£Í¬Ê±ÖÎÁÆ×éIFN£­¦Ã¡¢

¶ÔÕÕ×éÒ²¸ÄÉÆÏÔÖø¡£ÌáʾÁù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÖÎÁÆ·ÎÆ¢ÆøÐéÐͶùÍ¯Ïø´­ÖÎÁÆÐ§¹ûÃ÷È·£¬¿ÉÏÔÖø»º½âÁÙ´²Ö¢×´£¬½µµÍ»¼¶ùÑ×ÐÔ·´Ó¦£¬¸ÄÉÆ·Î¹¦ÄÜ£¬²¢ÓÐÖúÓÚÌá¸ß»úÌåÃâÒß¹¦ÄÜ£¬Ìá¸ß»¼¶ùÔ¤ºó¡£²Î¿¼ÎÄÏ×

£Û1£Ý°²º£Ó¢£®Áù¾ý×ÓÌÀ½áºÏÎ÷Ò©ÖÎÁƶùÍ¯Ïø´­µÄÁÆÐ§£ÛJ£Ý£®ÁÙ´²Ò½Ñ§

2018£¬3£¨13£©£º122£­123£®Ñо¿Óëʵ¼ù£¬

£Û2£ÝMIWAN£¬NAGANOT£¬OHNISHIH£¬etal£®AnOpen£­Label£¬

Multi£­Institutional£¬£ÒandomizedStudytoEvaluatetheAdditiveEffectofaLeukotriene£ÒeceptorAntagonistonCoughScoreinPa-tientswithCough£­VariantAsthmaBeingTreatedwithInhaledCorti-costeroids£ÛJ£Ý£®KobeJMedSci£¬2018£¬64£¨4£©£ºE134£­E139£®£Û3£ÝÂíݼ£¬¼ÍÎÄÄÈ£®ÓñÆÁ·çÉ¢ºÏÁù¾ý×ÓÌÀ¼Ó¼õ¸¨ÖúÖÎÁÆÐ¡¶ùÏø´­»º½â

J£Ý£®ÖÐÒ½¶ù¿ÆÔÓÖ¾£¬2018£¬14£¨2£©£º32£­35£®ÆÚ184ÀýÁÙ´²¹Û²ì£Û

£Û4£ÝµË»ÆÖУ®ÓñÆÁ·çÉ¢ºÏÁù¾ý×ÓÌÀ¼Ó¼õ¸¨ÖúÖÎÁÆÐ¡¶ùÏø´­»º½âÆÚÁÙ

£®½¡¿µ±Ø¶Á£¬2018£¨17£©£º6£®´²ÓÐЧÂÊ·ÖÎö£ÛJ£Ý

£Û5£ÝÌÕº£Ñ࣮Áù¾ý×ÓÌÀÁªºÏ³£¹æÁÆ·¨ÖÎÁÆÄÑÖÎÐÔÏø´­ÁÙ´²¹Û²ì£ÛJ£Ý£®

2017£¬26£¨22£©£º180£­182£®Ë«×ãÓë±£½¡£¬

£Û6£ÝÁõÑÇ×ð£¬ÕÅ𩣬ѦÕ÷£¬µÈ£®Áù¾ý×ÓÌÀºÏÓñÆÁ·çÉ¢ÖÎÁÆÏø´­Ç¨ÑÓÆÚµÄ

£®ÖйúÖÐÎ÷Ò½½áºÏ¶ù¿ÆÑ§£¬2019£¬11£¨2£©£º117£­121£®ÁÙ´²Ñо¿£ÛJ£Ý

£Û7£ÝÌïÊÀÁ«£®°×ÈýÏ©ÊÜÌåÞ׿¹¼ÁÁªºÏÎüÈëÓü¤ËØÖÎÁÆÖÐÖØ¶ÈÏø´­µÄ

£®ÑøÉú±£½¡Ö¸ÄÏ£¬2019£¨35£©£º293£®Ó¦ÓÃЧ¹ûÑо¿£ÛJ£Ý

£Û8£Ý¹¬Õñ»ª£®è×½ÛÁù¾ý×ÓÌÀ¼Ó¼õºÍɳÃÀÌØÂÞÌæ¿¨ËÉ·ÛÎüÈë¼ÁÖÎÁÆÖ§

88

Áù¾ý×ÓÌÀÁªºÏ°×ÈýÏ©ÊÜÌåÞ׿¹¼Á¶Ô·Î - Ê¡ÂÔ - - IL - 4 - IL - 10±í´ïµÄÓ°Ïì - ÁõÃô - ͼÎÄ.doc ½«±¾ÎĵÄWordÎĵµÏÂÔØµ½µçÄÔ£¬·½±ã¸´ÖÆ¡¢±à¼­¡¢ÊղغʹòÓ¡
±¾ÎÄÁ´½Ó£ºhttps://www.diyifanwen.net/c41b0a2f0v375cln2z0an3ef8l940h6007qm_1.html£¨×ªÔØÇë×¢Ã÷ÎÄÕÂÀ´Ô´£©
ÈÈÃÅÍÆ¼ö
Copyright © 2012-2023 µÚÒ»·¶ÎÄÍø °æÈ¨ËùÓÐ ÃâÔðÉùÃ÷ | ÁªÏµÎÒÃÇ
ÉùÃ÷ :±¾ÍøÕ¾×ðÖØ²¢±£»¤ÖªÊ¶²úȨ£¬¸ù¾Ý¡¶ÐÅÏ¢ÍøÂç´«²¥È¨±£»¤ÌõÀý¡·£¬Èç¹ûÎÒÃÇ×ªÔØµÄ×÷Æ·ÇÖ·¸ÁËÄúµÄȨÀû,ÇëÔÚÒ»¸öÔÂÄÚ֪ͨÎÒÃÇ£¬ÎÒÃǻἰʱɾ³ý¡£
¿Í·þQQ£ºxxxxxx ÓÊÏ䣺xxxxxx@qq.com
ÓåICP±¸2023013149ºÅ
Top